There was no benefit to extending zoledronate treatment beyond 2 years.
The current scientific evidence may not be generalizable to underrepresented groups.
Geographic location of radiology practice, breast subspecialization, performing diagnostic mammography tied to radiologist performance.
Although nearly all metrics improved for racial-ethnic minorities, recent breast cancer-related mortality in Florida still higher in Black women.
Among patients with stage I HER2+ breast cancer, adjuvant treatment with T-DM1 was associated with “excellent” 3-year iDFS, but was not associated with fewer clinically relevant toxicities compared with paclitaxel plus trastuzumab.
Use of clomiphene citrate or gonadotropins, alone or in combination, not associated with increased risk for breast cancer.
Overall survival was similar with pembrolizumab and single-agent chemotherapy.
Decline especially noticeable among women of racial and ethnic minority groups with low incomes.
The study showed differences in receipt of chemotherapy and surgery but not radiotherapy.
Rapid recommendation provides updated guidance on the use of adjuvant olaparib.
Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
Researchers observed a “sharp” decline in public interest.
The overall treatment effect in global health status/quality of life was similar between the treatment arms.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
No significant difference found in disease-free survival, overall survival, distant disease-free survival for five versus two years of treatment.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
The use of hypofractionated whole-breast irradiation increased significantly from 2004 to 2016.
The mutation rate was significantly higher in metastatic breast cancer than in nonmetastatic breast cancer.